The Role of Hyperuricemia in Cardiac Diseases: Evidence, Controversies, and Therapeutic Strategies

Yue Zheng1,2, Zhirui Chen1,2, Jinya Yang1,2

  • 1Guangdong Provincial Engineering Technology Research Center for Molecular Diagnosis and Innovative Drugs Translation of Cardiopulmonary Vascular Diseases, University Joint Laboratory of Guangdong Province and Macao Region on Molecular Targets and Intervention of Cardiovascular Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China.

Biomolecules
|July 27, 2024
PubMed

Insights

High uric acid levels (hyperuricemia) can harm heart cells, increasing the risk of heart disease. Lowering uric acid may help, but more research is needed to understand the exact mechanisms.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pathology

Background:

  • Hyperuricemia (HUA) is linked to myocardial cell damage and adverse cardiovascular outcomes.
  • HUA is associated with conditions like myocardial infarction, arrhythmias, and heart failure.

Purpose of the Study:

  • To review current clinical and basic research on HUA's impact on myocardial injury.
  • To explore the mechanisms by which HUA causes cardiac damage.
  • To discuss therapeutic interventions for lowering uric acid in cardiovascular disease.

Main Methods:

  • Review of clinical research progress.
  • Analysis of basic research findings on pathological models.
  • Exploration of molecular mechanisms linking HUA to myocardial injury.

Main Results:

  • HUA can damage myocardial cells through inflammasome activation, impaired energy metabolism, and oxidative stress.
  • Mechanisms include NOD-like receptor protein 3 inflammasome activation, interference with cardiac energy metabolism, and enhanced oxidative stress via reactive oxygen species.
  • These pathways ultimately lead to decreased cardiac function.

Conclusions:

  • HUA contributes to myocardial injury and cardiovascular diseases through multiple pathways.
  • Lowering uric acid is a potential therapeutic strategy, but requires further investigation.
  • Further research is essential to elucidate the mechanisms and develop effective treatments for HUA-related cardiovascular diseases.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
613
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
765